Motoneuron excitability and muscle spasms are regulated by 5-HT 2B and 5-HT 2C receptor activity. diately after spinal cord injury (SCI), a devastating paralysis results from the loss of brain stem and cortical innervation of spinal neurons that control movement, including a loss of serotonergic (5-HT) innervation of motoneurons. Over time, motoneurons recover from denervation and function autonomously, exhibiting large persistent calcium currents (Ca PICs) that both help with functional recovery and contribute to uncontrolled muscle spasms. Here we systematically evaluated which 5-HT receptor subtypes influence PICs and spasms after injury. Spasms were quantified by recording the long-lasting reflexes (LLRs) on ventral roots in response to dorsal root stimulation, in the chronic spinal rat, in vitro. Ca PICs were quantified by intracellular recording in synaptically isolated motoneurons. Application of agonists selective to 5-HT 2B and 5-HT 2C receptors (including BW723C86) significantly increased the LLRs and associated Ca PICs, whereas application of agonists to 5-HT 1 , 5-HT 2A , 5-HT 3 , or 5-HT 4/5/6/7 receptors (e.g., 8-OH-DPAT) did not. The 5-HT 2 receptor agonistinduced increases in LLRs were dose dependent, with doses for 50% effects (EC 50 ) highly correlated with published doses for agonist receptor binding (K i ) at 5-HT 2B and 5-HT 2C receptors. Application of selective antagonists to 5-HT 2B (e.g., RS127445) and 5-HT 2C (SB242084) receptors inhibited the agonist-induced increase in LLR. However, antagonists that are known to specifically be neutral antagonists at 5-HT 2B/C receptors (e.g., RS127445) had no effect when given by themselves, indicating that these receptors were not activated by residual 5-HT in the spinal cord. In contrast, inverse agonists (such as SB206553) that block constitutive activity at 5-HT 2B or 5-HT 2C receptors markedly reduced the LLRs, indicating the presence of constitutive activity in these receptors. 5-HT 2B or 5-HT 2C receptors were confirmed to be on motoneurons by immunolabeling. In summary, 5-HT 2B and 5-HT 2C receptors on motoneurons become constitutively active after injury and ultimately contribute to recovery of motoneuron function and emergence of spasms.
I N T R O D U C T I O N
After spinal cord injury (SCI), debilitating spasms often develop in the muscles innervated from the spinal cord below the injury, and this is the hallmark of the general spasticity syndrome after SCI Gorassini et al. 2004; Kawamura et al. 1989; Kuhn and Macht 1948) . Spasms involve simultaneous contractions of many muscles, lasting anywhere from seconds to minutes, and are triggered by brief innocuous sensory stimuli, such as cutaneous inputs. Upward of 80% of spinal cord-injured humans have spasms and general spasticity that can disrupt residual motor function, cause debilitating pain, and interrupt sleep (Maynard et al. 1990 ). Treatment of spasms with conventional antispastic drugs such as baclofen is often not adequate or not tolerated because of adverse side effects such as lethargy and weakness (Dario and Tomei 2004) .
Here we explore whether activity in one or more of the many 5-HT receptor subtypes facilitates spasms and examine whether selectively blocking these receptors may serve as a target for novel antispastic treatment.
The neuronal mechanisms underlying spasms have recently been identified in a rat model of SCI Harvey et al. 2006b; Li et al. 2004a; Murray et al. 2010) , and similar mechanisms have been shown to underlie spasms in humans Norton et al. 2008) . Briefly, these studies have shown that, immediately after SCI, motoneuron excitability plummets; in particular, there is a loss of low voltage-activated persistent calcium and sodium currents (persistent inward currents; Ca and Na PICs) that are normally crucial for enabling motoneurons to produce sustained motoneuron discharges in response to synaptic inputs (Heckman et al. 2005; Hultborn et al. 2004; Li et al. 2004a ). Many motoneurons are acutely so impaired that they can only fire transiently and can no longer follow synaptic inputs with appropriate firing (Harvey et al. 2006c) . However, over the months after injury (chronic injury), PICs spontaneously return, attaining high levels likely only seen in alert awake animals (Button et al. 2008; Harvey et al. 2006c; Hultborn et al. 2004; Li et al. 2004b ). Theses PICs are crucial for the recovery of motoneuron firing ability, enabling motoneurons to produce sustained firing and associated muscle contractions in response to transient inputs (Li et al. 2004a ). However, these PICs are permanently facilitated and, whenever these voltagedependent currents are activated by a brief synaptic depolarization, they are difficult to terminate because of the loss of normal descending control of inhibitory inputs to motoneurons with SCI (Holstege and Bongers 1991; Jankowska and Hammar 2002; Nielsen et al. 2007; Rekling et al. 2000) . Thus, activity in PICs causes uncontrolled motoneuron firing and associated muscle spasms Li et al. 2004a ). To make matters worse, after SCI, there is a general loss of inhibition over sensory afferent transmission (disinhibition) (Hochman et al. 2001; Lundberg 1982; Schmidt and Jordan 2000) , leading to unusually large and prolonged polysynaptic excitatory postsynaptic potentials (EPSPs) on motoneurons (Baker and Chandler 1987; Bennett et al. 2004; Li et al. 2004a ). These EPSPs readily trigger the large PICs in chronic SCI, which in turn produce many seconds of uncontrolled motoneuron firing. Thus spasms are readily triggered by transient sensory stimulation ).
Brain stem-derived serotonin (5-HT) plays a critical role in regulating normal levels of spinal cord excitability by several receptors (Hochman et al. 2001; Schmidt and Jordan 2000) , including facilitating Ca PICs on motoneurons by activating 5-HT 2 receptors (Harvey et al. 2006a; Heckman et al. 2005; Perrier and Delgado-Lezama 2005) and by inhibiting sensory afferent transmission by activating 5-HT 1 receptors (Hochman et al. 2001; Millan 2002; Schmidt and Jordan 2000; Yoshimura and Furue 2006) . Thus, the immediate loss of motoneuron excitability and emergence of large EPSPs acutely after spinal transection is partly explained by a loss of 5-HT. The spontaneous recovery of motoneuron excitability (e.g., PICs) over the months after injury (chronic spinal rat) is more difficult to explain, but recently Harvey et al. (2006b) suggested that it involves re-activation of 5-HT 2 receptors. Furthermore, Murray et al. (2010) have recently shown that this activation of the 5-HT 2 receptors occurs in the absence of 5-HT after injury; that is, the receptors become constitutively active, as described in other systems (Aloyo et al. 2009; Seifert and Wenzel-Seifert 2002) . These two studies do not clearly define which specific 5-HT 2 receptor is involved, although both suggest it could be the 5-HT 2C receptor, and Harvey (2006b) speculated that 5-HT 2A receptors may be involved as well. Little is known about the role of other 5-HT receptors in motoneuron function and spasms after injury. Furthermore, because mostly nonselective pharmacological agents (e.g., 5-HT 2A/2B/2C receptor agonist DOI) have been used to study 5-HT modulation of normal motoneuron function, it even remains unclear which receptors are specifically involved in normal animals, although these seem to include the Gq-protein coupled 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors (Elliott and Wallis 1992; Harvey et al. 2006a; Holohean and Hackman 2004; Wang and Dun 1990) , Gi coupled 5-HT 1A receptors (Holohean et al. 1990; Wang and Dun 1990) , Gs-coupled 5-HT receptors like 5-HT 7 receptors that increase cAMP (Inoue et al. 2002; Larkman and Kelly 1997) , and possibly ionotropic 5-HT 3 receptors (Ziskind-Conhaim et al. 1993) .
In this study, we use numerous 5-HT agonists and highly selective antagonists to determine which receptors facilitate motoneuron function (Ca PICs) and associated long-lasting reflexes (spasms) after SCI, by correlating agonist potency at facilitating the spasms with the published binding affinity of these agonists to all 5-HT receptor types (Barnes and Sharp 1999; Boess and Martin 1994) . We determine whether spontaneous activity in these receptors contributes to recovery of PICs and emergence of spasms and examine whether this activity results from either residual 5-HT in the caudal spinal cord or constitutive receptor activity (Murray et al. 2010; Seifert and Wenzel-Seifert 2002) .
M E T H O D S
Recordings were made from motoneurons and associated ventral roots of the sacrocaudal spinal cord of spastic adult rats with chronic SCI (3.5-5 mo old) . Adult female rats were transected at the S 2 sacral level at about 2 mo of age (adult rat), and recordings were made after their affected muscles became spastic (1.5-3 mo after injury), as detailed previously . All recordings were made from the whole sacrocaudal spinal cord that was removed from the rat with an S 2 sacral transection and maintained in vitro (Li et al. 2004b ). This transection was made just rostral to the chronic spinal injury, to not further damage the sacrocaudal cord. All experimental procedures were approved by the University of Alberta Animal Care and Use Committee: Health Sciences.
In vitro preparation
Details of the in vitro experimental procedures have been described in previous publications (Harvey et al. 2006c; Li et al. 2004a,b; Murray et al. 2010) . Briefly, all the rats were anesthetized with urethane (0.18 g/100 g; with a maximum dose of 0.45 g), and the sacrocaudal spinal cord was removed and transferred to a dissection chamber containing modified artificial cerebrospinal fluid (mACSF). Spinal roots were removed, except the sacral S 4 and caudal Ca 1 ventral roots and the Ca 1 dorsal roots. After 1.5 h in the dissection chamber (at 20°C), the cord was transferred to a recording chamber containing normal ACSF (nACSF) maintained near 24°C, with a flow rate Ͼ5 ml/min. A 1-h period in nACSF was given to wash out the residual anesthetic and mACSF before recording, at which time the nACSF was recycled in a closed system with a peristaltic pump (Harvey et al. 2006b ).
Ventral root reflex recording and averaging
Dorsal and ventral roots were mounted on silver-silver-chloride wires above the nASCF of the recording chamber and covered with a 1:1 mixture of petroleum jelly and mineral oil (as for intracellular recording) for monopolar stimulation and recording (Li et al. 2004b ). We evoked ventral root reflexes with a low-threshold Ca 1 dorsal root stimulation (single pulse, 0.1 ms, 0.02 mA, corresponding to 3x afferent threshold, 3ϫT; afferent and reflex threshold are similar; Bennett et al. 2004 ) using a constant current stimulator (Isoflex, Israel) . This stimulation intensity (3ϫT) is compatible with activation of low-threshold group I and II (A␤) afferents. Because the Ca 1 dorsal root innervates the distal third of the tail, which lacks large muscles , this stimulation activates largely cutaneous or joint afferents. However, there are small intrinsic muscles in the tail with group Ia and II muscle afferents (Steg 1964) , and thus to a lesser extent, muscle afferents may be activated. The stimulation was repeated five times at 10-s intervals for each trial. The ventral root recordings were amplified (ϫ2,000), high-pass filtered at 100 Hz, low-pass filtered at 3 kHz, and recorded with a data-acquisition system sampling at 6.7 kHz (Axonscope 8, Axon Instruments). Ventral root reflexes were quantified using custom written software (Matlab, MathWorks, Natick, MA). That is, data were high pass filtered at 800 Hz and rectified to allow averaging (Fig. 1A, bottom) . We quantified the long-latency, long-lasting reflex (LLR) by averaging the rectified response 500 -4,000 ms after stimulus, a period where the response is mainly determined by the motoneuron Ca PIC activity and not by stimulus evoked synaptic inputs, which end by about 500 ms. Average ventral root activity was averaged for all five stimuli in a trial. This recording procedure was repeated at 12-min intervals, and 5-HT receptor agonists were added immediately after each recording, giving them time to fully act by the next recording session. Cumulative dose-response relations were computed by increasing agonist doses at these 12-min intervals (0.003, 0.01, 0.03. 0.1, . . . , 30 M doses used). Antagonists took longer to act, and responses reached near steady state typically Ͼ20 min after application, at which time responses were averaged. The effect of agonists on the reflexes were reversible on washout of the agonist, but full recovery to baseline only occurred after several hours, likely because of the large size of the whole cord preparation. Thus washout of agonists was not feasible between doses of the agonists used in the construction of dose-response relations.
Intracellular recording
Sharp intracellular electrodes were made from glass capillary tubes (1.5 mm OD, Warner GC 150F-10) using a Sutter P-87 micropipette puller and filled with a combination of 1 M potassium acetate and 1 M KCl. Electrodes were beveled down from an initial resistance of 40 -80 to 26 -32 M⍀ using a rotary beveller (Sutter BV-10). A stepper-motor micromanipulator (660, Kopf) was used to advance the electrodes through the ventral cord surface into motoneurons. Large 30-m forward and backward steps were initially required to breach the white matter (about 100 m thick). Multiple tracks were made in the gray matter with 2-m steps, without coming completely out of the white matter, by moving the electrode sideways in the white matter before each new tract (to further weaken pia and improve stability). Penetrations were made with capacitance-over-compensation ringing. After penetration, motoneuron identification was made with antidromic ventral root stimulation, and noting ventral horn location, input resistance and time constant (Ͼ6 ms for motoneurons) ). Cells were always held below rest (Ͻ Ϫ70 mV) with a small continuous bias current to assure that the Ca PICs were not even partly activated before testing, because the Ca PIC slowly deactivates if it is activated for a few minutes and does not recover from this deactivation for many minutes (unpublished data). Data were collected with an Axoclamp 2b intracellular amplifier (Axon Instruments, Burlingame, CA) running in discontinuous current clamp (DCC, switching rate 4 -6 kHz, output bandwidth 3.0 kHz, sample rate of 6.7 kHz) or discontinuous single-electrode voltage clamp (SEVC; gain, 0.8 -2.5 nA/mV) modes.
Slow triangular voltage ramps (3.5 mV/s voltage clamp) were applied to the motoneurons to measure their electrical properties, as detailed previously (Harvey et al. 2006c; Li et al. 2004a ). The input resistance (R m ) was measured during the voltage ramps over a 5-mV range near rest and subthreshold to PIC onset. Resting potential (V m ) was recorded with 0-nA bias current, after the cell had been given about 15 min to stabilize after penetration. The slow triangular voltage ramps were used to directly measure the PICs as follows (shown in Fig. 5A ). During the upward portion of this ramp, the current response initially increased linearly with voltage in response to the passive leak conductance. A linear relation was fit in the region just below the PIC onset (5 mV below) and extrapolated to the whole range of the ramp (leak current; thin line in Fig. 5A ). At depolarized potentials above the PIC onset threshold, there was a downward deviation from the extrapolated leak current, and the PIC was estimated as the difference between the leak current and the total current (initial peak current at arrow in Fig. 5A ; leak-subtracted current). The onset voltage for the PIC (V on ) was defined as the voltage at which the slope of the current response initially reached zero (Li and Bennett 2003) . Finally, the excitatory postsynaptic potential (EPSP) and associated reflexes were measured in motoneurons by stimulating the Ca 1 dorsal roots (at 3xT, as in ventral root reflex recording) while applying hyperpolarizing bias currents to block the PICs (Fig. 1C, bottom) .
Drugs and solutions
Two kinds of ACSF were used in these experiments: mACSF in the dissection chamber before recording and nACSF in the recording chamber. The mACSF was composed of (in mM) 118 NaCl, 24 NaHCO 3 , 1.5 CaCl 2 , 3 KCl, 5 MgCl 2 , 1.4 NaH 2 PO 4 , 1.3 MgSO 4 , 25 D-glucose, and 1 kynurenic acid. nACSF was composed of (in mM) 122 NaCl, 24 NaHCO 3 , 2.5 CaCl 2 , 3 KCl, 1 MgCl 2 , and 12 D-glucose. Both types of ACSF were saturated with 95% O 2 -5% CO 2 and maintained at pH 7.4. The drugs added to the ACSF were 5-HT, DOI[(Ϫ)(R)-DOI hydrochloride] (from Sigma-Aldrich), 2-methyl-5-HT, 8-OH-DPAT, AC90179, ␣-methyl-5-HT, BW723C86, clozapine, cisapride, cyproheptadine, EMD386088, granisetron, isradipine, ketanserin, LP44, LY344864, methylergonovine, methysergide, MK212, prazosin, RS102221, RS127445, SB204741, SB206553, SB224289, SB242084, tryptamine (all from Tocris), TTX (TTX-citrate; Alomone), and zolmitriptan (kindly donated by Astra Zeneca). All drugs were first dissolved as a 10 -50 mM stock in water before final dilution in ACSF, with the exception of BW723C86, RS102221, RS127445, cisapride, clozapine, SB204741, and prazosin, which were dissolved in minimal amounts of DMSO (final concentration in ACSF Ͻ0.04%; by itself, DMSO had no effect on the LLR in vehicle controls). During intracellular recording, we usually first blocked the sodium currents (fast and persistent) and synaptic transmission with 2 M TTX and then examined the Ca PIC sensitivity to 5-HT ligands. The Ca PIC was verified to be L-type calcium channel mediated by its blockage by dihydropiridines (nimodipine or isradipine; 15 M).
Immunolabeling
Rats were killed with Euthanyl (Bimeda-MTC; 700 mg/kg) and perfused intracardially with 100 ml saline followed by 400 ml 2% paraformaldehyde (PFA; in phosphate buffer at room temperature; over about 15 min). Spinal cords were postfixed in PFA for 90 min at 4°C, cryoprotected in 20% sucrose and 2% ethylene-glycol, frozen, and cut on a cryostat in horizontal or transverse 25-to 40-m sections. Spinal cord sections were incubated overnight at 4°C with primary antibodies: goat anti-5-HT 2B receptors (1:500, Santa Cruz SC-15081, Santa Cruz) and mouse anti-SMI32 (1:1,000, Convance SMI-32R) in PBS. This specificity of this 5-HT 2B receptor antibody has previously been shown (Moran et al. 2008; Tadros et al. 2007 ). Antibody labeling was visualized with fluorescent secondary antibodies (5-HT 2B : donkey anti-goat conjugated with Alexa488, 1:400, Invitrogen A11055; SMI32: donkey anti-mouse conjugated with Alexa568, 1:500, Invitrogen A11037) for 90 min at room temperature. Image acquisition used a Zeiss LSM 510 laser-scanning confocal microscope: Plan-Apochromat 63ϫ 1.4 oil objective, BP 505-520, BP 560 -615, HFT 488/543 with lasers at 488 and 543 nm, acquisitions in multi-track mode, optical slice thickness 0.14 m. Controls in which the primary antibody was preabsorbed with the antigen that it was raised against were used to verify the selectivity of the antibody labeling. Also, controls in which the primary antibody was omitted were used to confirm that the secondary antibody produced no labeling by itself. SMI32 labels nonphosphorylated neurofilament H and does not change with SCI (Anelli et al. 2007) . We have previously shown that SMI32 labels motoneurons and not interneurons in the ventral horn, although it also labels large cells elsewhere in the brain. Thus SMI32 provides a fairly selective marker of motoneurons in the ventral horn (Anelli et al. 2007) , and in particular, labels the intracellular space (neurofilament).
Data analysis
Data were analyzed in Clampfit 8.0 (Axon Instruments) and Sigmaplot (Jandel Scientific) and expressed as mean Ϯ SD. A Student's t-test was used to test for statistical differences before and after drug applications, with a significance level of P Ͻ 0.05. A Kolmogorov-Smirnov test for normality was applied to each data set, with a P ϭ 0.05 level set for significance. Most data sets were found to be normally distributed, as is required for a t-test. For those that were not normal, a Wilcoxon signed rank test was instead used with a significance level of P Ͻ 0.05.
Standard sigmoidal curves were fit to the relation between agonist dose and reflex responses, with doses expressed in log units and with a Hill slope of unity. The dose that produced 50% effect (EC 50 ) was measured from the curve, and -log(EC 50 ) was used to quantify the drug potency: pEC 50 ϭ -log(EC 50 ). Also, the maximum drug-induced response (efficacy) was computed from the curve (peak of curve). For comparison to our computed potencies (pEC 50 ), the binding affinity of each drug at the rat 5-HT receptors was also reported, with values taken from the literature ( Table 1 ). The binding of an agonist to a receptor is expressed in terms of its K i value (nM), which corresponds to the dose that produces 50% binding to that receptor (Knight et al. 2004) . This is typically measured by the agonist's ability to displace a standard radio-labeled ligand, such as [ 3 H]-5-HT, from the receptor expressed in isolated cells. Binding affinity is computed as pK i ϭ -log(K i ) (Knight et al. 2004 ). When possible, binding affinities of different drugs for a given receptor were taken from large studies or summary reviews (Boess and Martin 1994) , usually using isolated cloned receptors. Also, high affinity agonist-preferring binding sites were always used, measured with radioactive agonists (usually [ 3 H]-5-HT), rather than radioactive antagonists that bind to a low-affinity site (Egan et al. 2000; Knight et al. 2004 ). If rat receptor K i values were not available, human values were used instead, because these are similar for most receptors (Boess and Martin 1994) .
DOI is one of the few 5-HT 2 agonists that is very selective to only 5-HT 2 receptors (it activates just 5-HT 2A/2B/2C ) (Boess and Martin 1994) , and accordingly, its dose-response relation was a simple sigmoidal relation. In contrast, other agonists such as ␣-methyl-5-HT bind nonselectively to other 5-HT receptors, although with much less affinity than to 5-HT 2 receptors (Table 1) . With these drugs, the dose-response relation was mostly sigmoidal, until higher doses were reached, at which point the LLR tended to decrease with increasing dose, consistent with a nonselective action on other receptors. To minimize the effect of this nonselective receptor activation, only the main part of the dose-response relation with increasing responses to increasing dose (over 2 decades) was fit to the sigmoidal doseresponse relation to obtain an estimate of the EC 50 . We used a Hill slope of 1.0 (see above) to force the sigmoid to have a fixed width of about 2 decades (2 orders of magnitude in dose, as is expected for the response to a single receptor). This approach caused the low doseresponses of agonists (e.g., selective 5-HT 2B agonists) to dominate the sigmoidal fit where they are most selective and assured that the EC 50 was not affected (e.g., underestimated) by the nonselective action of other 5-HT receptors that may have affected (e.g., inhibited) the LLR at high doses.
R E S U L T S

Use of LLRs as a measure of Ca PICs and spasms in chronic spinal rats
When the dorsal roots of the in vitro sacrocaudal spinal cord were stimulated with a low-threshold current (3ϫT), a longlasting reflex (LLR; 2-to 10-s duration) was evoked in motoneurons, as recorded both from ventral roots ( Fig. 1A ) and from single motoneurons measured intracellularly (Fig. 1C , top). The many-second-long portion of this LLR is mediated by a large persistent inward calcium current (Ca PIC) that activates a plateau potential and associated sustained firing in motoneurons of chronic spinal rats (Li et al. 2004a ), which we verified with two methods. First, directly blocking the Ca PIC (with isradipine or nimodipine; 15 M) largely eliminated the LLR (significantly reduced by 83.9 Ϯ 7.9%, n ϭ 9, P Ͻ 0.05; Fig. 1B ), and second, hyperpolarizing motoneurons to prevent activation of the voltage-dependent Ca PIC eliminated the LLR and associated PIC-mediated plateau (Fig. 1C , bottom; n ϭ 10/10). In both cases, eliminating the Ca PIC left an ϳ0.5-slong response that was caused by a polysynaptic EPSP in the motoneurons (Fig. 1, B and C, bottom) . For this study, we focused on the Ca PIC and use the LLR reflex measured at times Ͼ0.5 s as an indirect estimate of this Ca PIC on motoneurons (Fig. 1A , bottom; rectified response averaged in a 0.5-to 4-s window). This enabled us to efficiently screen many 5-HT drugs and doses with simple ventral root, rather than intracellular motoneuron, recordings. Previous work has shown that the LLR we record in vitro also occurs in vivo in the awake chronic spinal rat, where it produces muscle spasms Murray et al. 2010) . Thus the LLR recorded in vitro is also a convenient assay of spasms, and we used it to assess which 5-HT receptors modulate spasms.
Only 5-HT 2B and 5-HT 2C receptors facilitate the LLR Application of 5-HT 2 receptor agonists (␣-methyl-5-HT, DOI, BW723C86, methylergonovine, MK212, 2-methyl-5-HT, tryptamine, and 5-HT) increased the LLR (Fig. 2) , with increasing doses generally producing larger responses over about a 100-fold change in dose (e.g., 10 -1,000 nM for ␣-methyl-5-HT; Fig. 2D ). This agonist dose-response relation was well approximated by a sigmoidal curve (Fig. 2, C and D) , from which we computed the agonist dose to produce 50% maximal effect (EC 50 ; Fig. 2D ), agonist potency [pEC 50 ϭ -log(EC 50 )], and efficacy (maximal response; Fig. 2C ). All 5-HT 2 agonists tested exhibited a significant efficacy in facilitating the LLR (Table 2) , with efficacy reported as a percent of mean 5-HTinduced LLR, which was 0.393 Ϯ 0.19 mV. This 5-HTinduced LLR was three times greater than the predrug LLR of 0.11 Ϯ 0.06 mV (100% in Table 2 represents a 3-fold change in LLR). Agonists that are known to bind to both 5-HT 2B and 5-HT 2C receptors (K i Ͻ 50 nM; ␣-methyl-5-HT, DOI, 5-HT) consistently had the highest efficacies, including 5-HT. Agonists that bind relatively selectively to either 5-HT 2B receptors (BW723C86, methylergonovine, 2-methyl-5-HT; i.e., K i for 5-HT 2B about 10 times higher than 5-HT 2C ; Table 2 ) or 5-HT 2C receptors (MK212; or agonists made selective by antagonists, e.g., ␣-methyl-5-HT acts as a selective 5-HT 2C agonist when given with the 5-HT 2C antagonist RS127445 present; Fig. 2C ; Table 2 ) had significantly lower efficacies. However, the sum of the effects of selective 5-HT 2B and 5-HT 2C agonists was similar to the effect of broad-spectrum 5-HT 2 agonists (␣-methyl-5-HT and 5-HT, Table 2 ), suggesting that both 5-HT 2B and 5-HT 2C receptors are required to maximally facilitate the LLR.
Prior application of antagonists that blocked both 5-HT 2B and 5-HT 2C receptors (including SB206553, clozapine, cyproheptadine, methysergide, or a combination of RS127445 and RS102221) inhibited the 5-HT 2 agonist-induced increase in LLR (Fig. 2 , C and D; Table 2 ), eliminating responses to all but the highest doses and significantly reducing the LLR induced by the agonist dose that maximally facilitated the LLR before the antagonists (SB206553 reduced LLR to 15.9 Ϯ 25.7, 4.1 Ϯ 13.2, and 1.0 Ϯ 8.2% of preantagonist efficacy for ␣-methyl-5-HT, DOI, and 5-HT, respectively). The antagonist application shifted the dose-response relation to such high doses that the standard sigmoidal curve with 100-fold dose range could Agonists K i and binding affinity (pK i ϭ Ϫlog K i ) obtained from high affinity agonist radioligand bindings studies (Adham et al. 1996; Baxter 1996; Boess and Martin 1994; Boess et al. 1997; Egan et al. 2000; Engel et al. 1986; Glennon et al. 1989; Hoyer et al. 1985; Kennett et al. 1997a; Knight et al. 2004; Leopoldo et al. 2007; Martin et al. 1997; Mattsson et al. 2005; Milburn and Peroutka 1989; Phebus et al. 1997) , with references abbreviated by the first few letters of authors' names, except for Boess et al. 1997 , which is abbreviated as B97. Methylergonovine is abbreviated as methylergon. Each agonist is considered to activate a receptor if K i Ͻ 400 nM and is listed with that receptor. Cisapride binds to other receptors but was only used after blocking all but 5-HT 4 receptors (Table  2) , and so is only listed with that receptor.AQ: Au please spell out DOI. no longer be fit to the few responsive high doses tested, and the usual EC50 measurements were thus not detectable (ND; Table  2 ). This thorough inhibitory action of these antagonists suggests that 5-HT 2B and/or 5-HT 2C receptors facilitate the LLR. Furthermore, the finding that the facilitation of the LLR by 5-HT itself is blocked by these combined 5-HT 2B and 5-HT 2C antagonists indicates that all other 5-HT receptors (including 5-HT 2A ) are likely not involved in facilitating the LLR or PIC.
Prior application of the selective 5-HT 2B receptor antagonist SB204741 significantly inhibited the effect of the selective 5-HT 2B agonist BW723C86 (decreasing the potency, doubling the EC 50 , and decreasing the efficacy; Table 2 ), consistent with the involvement of 5-HT 2B receptors. However, the response to BW723C86 was not completely eliminated by SB204741, likely because of the weak action of BW723C86 on the 5-HT 2C receptor (We thus consider BW723C86ϩSB204741 a weak 5-HT 2C agonist in Table 3 , described below.) Blocking all 5-HT 2 receptors except the 5-HT 2B receptor (with 5-HT 2C and 5-HT 2A antagonists) did not eliminate the facilitation of the LLR by subsequent application of the 5-HT 2 receptor agonist ␣-methyl-5-HT (Table  2) and did not significantly shift the dose-response curve (EC 50 not altered significantly), although the efficacies were lowered (Table 2) . Similarly, blocking all but the 5-HT 2C receptor did not eliminate the ␣-methyl-5-HT-induced LLR or significantly shift the EC 50 (Table 2) . This is consistent with the involvement of both the 5-HT 2B and 5-HT 2C receptors in facilitating the LLR; the EC 50 was not significantly shifted with a block of either 5-HT 2B or 5-HT 2C receptors, because ␣-methyl-5-HT binds with similar affinity to 5-HT 2B and 5-HT 2C receptors (Table 1) .
Application of selective agonists (or agonist/antagonist combinations) for other 5-HT receptors (5-HT 1 , 5-HT 2A , 5-HT 3 , 5-HT 4 , 5-HT 5 , 5-HT 6 , 5-HT 7 ) produced no significant facilitation of the LLR even at high doses (3-10 M; Table 2 ), again suggesting that only 5-HT 2B and 5-HT 2C receptors facilitate the LLR.
Agonist potency is correlated with receptor binding affinity at 5-HT 2B and 5-HT 2C receptors
The effective 5-HT 2 agonist doses required to facilitate the LLR (EC 50 values and associated potencies, pEC 50 ) varied by orders of magnitude between the different agonists (or agonist/ antagonist combinations). However, this variation was largely . Each plot shows the typical response from a single rat, with a different rat for each condition, because agonists are not feasible to wash out and repeat after antagonist application (taking many hours to wash).
accounted for by the differing binding affinity of these drugs to 5-HT 2B and 5-HT 2C receptors (pK i ; see description of binding affinity in METHODS). That is, we found that the agonist potencies in facilitating the LLR (pEC 50 and associated EC 50 ) were significantly correlated with the binding affinity of these agonists (pK i ) for 5-HT 2B (r ϭ 0.93, slope ϭ 0.95, n ϭ 8 drugs combinations tested, P Ͻ 0.05) and 5-HT 2C (r ϭ 0.77, slope ϭ 0.89, n ϭ 8, P Ͻ 0.05) receptors, as shown in Fig. 3 , B and C. Interestingly, a line with unity slope (pEC 50 ϭ pK i ϩ C, where C is a fixed value) was equally well fit to the data, with r ϭ 0.92 and r ϭ 0.77 for 5-HT 2B and 5-HT 2C receptors, respectively ( Fig. 3, A and B) , a useful finding that we use in the next section to model the potency-affinity relation to further predict which receptors modulate the LLR. In contrast, there was no significant correlation with the potency and the binding affinity for 5-HT 2A receptors (r ϭ 0.31, n ϭ 8, P Ͼ 0.05) or any other receptor (Fig. 3) , and points were scattered far from the unity slope line that fit the 5-HT 2B and 5-HT 2C receptors.
Potency of each agonist can be quantitatively predicted from its receptor binding affinity
To directly compensate for the variable receptor binding affinity of different agonists, we computed the potency of each agonist in facilitating the LLR relative to its binding affinity at each receptor, which we term the relative potency ϭ pEC 50 Ϫ pK i . As we just mentioned, this difference is a fixed constant (C ϭ relative potency) for the receptors involved in modulating the LLR (5-HT 2B and 5-HT 2C ), and thus we expect that it should be invariant when computed with pK i values for functional receptors in the spinal cord (5-HT 2B ) but variable for other receptors. This relative potency should account for all factors that affect potency (e.g., drug diffusion, receptor signaling) other than receptor binding. As shown in Table 3 , the relative potency computed for all agonists of the 5-HT 2B receptor was indeed very similar, all falling within the 99% confidence interval (Ϯ0.58) about the mean relative potency [-1.02 Ϯ 0.32 (SD)], and within 2 SD of this mean, which we set as the similarity criterion. The relative potency of agonists at the 5-HT 2C receptor was likewise invariant, clustered remarkably near the mean value of -1.03 Ϯ 0.49 and not significantly different from the relative potency at the 5-HT 2B receptor (Table 3) . Again, most 5-HT 2C agonists had relative potencies within the 99% confidence interval about the mean (Ϯ0.53), and within 2 SD of the mean, consistent with the interpretation that 5-HT 2C receptors also play a role in modulating the LLR (see also Fig. 3, squares) . The only exception was DOI, which had a response that was dominated by the 5-HT 2B , rather than the 5-HT 2C , receptor. These findings suggest that, after taking into account variable binding affinity, all these 5-HT 2 agonists appeared to diffuse equally well to common targets (the 5-HT 2B and 5-HT 2C receptors) and have similar actions (facilitating the Ca PIC underlying the LLR). Receptor binding affinities (pK i and K i values) are typically measured in homogenized membranes from isolated cells (transfected with cloned receptors, Boess and Martin 1994; Knight et al. 2004) . In contrast, we measured the functional effects of these agonists (the potency or EC 50 ) in a whole spinal cord preparation, where there are substantial barriers to drug diffusion to the receptors. Furthermore, downstream actions of receptor binding may further alter the potency (see DISCUSSION). Thus it is not unexpected that the EC 50 exceeds the Agonists with varying selectivity for the different 5-HT receptors were applied, sometimes after prior application of 5-HT receptor antagonists to effectively make the agonist action more selective (column 2, pretreatment, starting Ͼ 30 min before agonist). The receptors that can be activated by this agonist/antagonist combination are indicated in column 3, with high binding affinity for the agonist listed first (with K i about 1-50 nM), followed by moderate affinity (in brackets; K i ϭ 50 -400 nM; see Table 1 ). Antagonist abbreviations and receptors blocked are as follows: RS127445 (RS127, 5-HT 2B ); RS102221 (RS102, 5-HT 2C ); AC90179 (AC901, 5-HT 2A ); SB206553 (5-HT 2B/2C ); SB204741 (5-HT 2B ), SB224289 (5-HT 1B ), prazosin (␣1 adrenergic); granisetron (5-HT 3 ); methysergide (5-HT 2 ), and clozapine (5-HT 2 ). Antagonist doses are given in Table 4 , except for prazosin (1 M), granisetron (0.3 M) and SB224289 (1 M). The efficacy (maximal effect) of these agonists in facilitating the LLR is indicated in column 6 (max mean rectified LLR, normalized by 5-HT efficacy). When a significant facilitation (efficacy) was detected, the mean agonist potency was computed, from which the EC 50 was computed (potency ϭ ϪlogEC 50 ). In addition to the agonists shown, no detectable facilitation (ND, P Ͼ 0.05) occurred with application of the agonists: 8-OH-DPAT, cisapride (RS), EMD386088, LP44, LY34864, and zolmitriptan when given up to 3-10 M doses, ruling out the involvement of the receptors that these drugs selectively activate [see Table 1 for K i values; cisapride given after pretreatment with antagonists RS127445, RS1022221, granisetron and prazosin to make it selective to 5-HT 4 receptors, which is abbreviated cisapride (RS)]. Also after some antagonist pre-treatments (SB206553), there was no detectable (indicated ND) facilitation of the LLR at all but the highest doses, making it impossible to estimate EC 50 . ϩ between antagonists indicates they were given in combination. *Efficacy significantly different from zero (LLR significantly increased), P Ͻ 0.05. †Pretreatment with methysergide, clozapine, or RS127445 ϩ RS102221 also eliminated the facilitation of the LLR by 5-HT (ND), like SB206553. ‡Potency significantly lowered by SB204741, P Ͻ 0.05. Data shown as mean Ϯ SD, with n Ͼ 8 per drug (or combination). K i dose value (potency Ͻ affinity) and the relative potency (potency Ϫ affinity) ϳ ϭ Ϫ1.0. Another way to interpret relative potency arises from the law of differences of logarithms
Thus the ratio EC 50 /K i ϭ 10 -C , which again should be a fixed number for a receptor involved in modulating the LLR. For the 5-HT 2B receptor, the overall EC 50 /K i was 10.0 1 , indicating that the EC 50 in the present whole sacral spinal cord preparation is about 10 times the K i value, which is likely because of common diffusion barriers. Our consistent findings of fixed relative potencies for 5-HT 2B and 5-HT 2C receptors suggest that perhaps, in general, we can predict the EC 50 and potency of drugs at a particular receptor from the published K i values (EC 50 ϭ 10 ϫ K i and potency ϭ affinity -1); receptors that do not consistently fit this prediction are unlikely to be functional (assuming similar diffusion to each receptor). The power of this modeling ap-proach is that the lack of involvement of a given receptor in the LLR can be proven by the potency measured from as little as one agonist, if that potency is far from the affinity (relative potency different from -1, and corresponding point far from the pEC 50 ϭ pK i -1 line in Fig. 3 ; e.g., 5-HT 2A cannot be involved because DOI exhibits a relative potency of -3 at this receptor). Indeed, we found that the relative potency at all other 5-HT receptors was highly variable, usually significantly different from the relative potency at the 5-HT 2B/2C receptors (Ͼ2 SD away from -1.0; Table 3 ; and scattered away from pEC 50 ϭ pK i -1 line in Fig. 3) , thus further ruling out the involvement of all but the 5-HT 2B and 5-HT 2C receptors. Occasionally, the relative potency fell close to -1.0 for a particular agonist, like methylergonovine at the 5-HT 2A receptor, but this was simply by chance, because the relative potency of other agonists at these receptors was not consistently -1.0. For example, MK212 has an impossibly high relative potency of ϩ0.36 at the 5-HT 2A receptor, with a corresponding EC 50 less than K i (Table 3; MK212 is a poor 5-HT 2A agonist). Furthermore, these receptors with inconsistent (Table 1) : pEC 50 -pK i . Pretreatment with antagonists used to make agonist more selective, indicated in brackets, abbreviated as in Table 2 . ND, no detected inhibition of the reflex in Table 2 . Relative potency not computed for methylergonovine at the 5-HT 2C receptor, because this drug has a much higher affinity for 5-HT 2B receptors, which dominate its response. Bold indicates receptors with relative potency values mostly within confidence interval. *relative potency within 2 SD of Ϫ1.0 (or the mean for 5-HT 2B receptors), the confidence interval for similarity, which is about 0.4 -0.6. relative potencies often had substantial binding affinity for agonists (like zolmitriptan at the 5-HT 1B receptor) that caused no detectable facilitation of the LLR (ND; Table 3 ). Thus we again conclude that only the 5-HT 2B and 5-HT 2C receptors are involved in facilitating the LLR.
Antagonist dose determination
The experiments described above partly rely on using a blocking dose of selective 5-HT 2 receptor antagonists before adding agonists, to identify the receptors involved in facilitating the LLR. The antagonist dose that we used was always chosen to be Ն10 times the published K i value of that antagonist at the target receptor (e.g., 5-HT 2 ; Table 4 , column 2), to account for drug diffusion into the whole cord preparation, as described above for agonists (assuming that the EC 50 of the antagonist can be predicted from its K i value, as for agonists: EC 50 ϭ 10 ϫ K i ) and typically set Ն100 times the K i to maximally block the receptor. Furthermore, to be sure that we did not affect other receptors nonselectively, we tried to use an antagonist dose that was less than about 10 times the K i value of that antagonist at other receptors known to bind this antagonist (Table 4 , column 3 shows the receptor most likely to be nonselectively activated, with the highest published K i value of all other receptors tested). Satisfying this latter criterion was not always possible for nonselective antagonists like methysergide.
5-HT 2B and 5-HT 2C receptor antagonists block the action agonists
To verify that we used 5-HT 2 receptor antagonists at an appropriate dose to block the 5-HT 2B/2C receptors in the experiments described above (e.g., Table 2 ), we directly tested the efficacy of most antagonists in inhibiting a prior dose of the 5-HT 2 receptor agonist ␣-methyl-5-HT (0.3 M). A submaximal agonist dose (near agonist EC 50 ; dose vs. time) was used to assure that the agonist only activated 5-HT 2 receptors. As shown in Fig. 3 and Table 4 , all 5-HT 2B/2C antagonists tested (selective and nonselective drugs) significantly decreased a prior agonist-induced increase in LLR. Importantly, the selective 5-HT 2B receptor antagonists (RS127445 and SB204741) and 5-HT 2C receptor antagonist (RS102221) each inhibited the LLR induced by the 5-HT agonist ( Table 4 ), confirming that both 5-HT 2B and 5-HT 2C receptors modulate the LLR and associated Ca PIC. In contrast, the 5-HT 2A receptor antagonist AC90179 had no effect (Table 4) . 
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FIG. 3. Potency of 5-HT receptor agonists at facilitating the LLR is only related to binding to 5-HT 2B and 5-HT 2C receptors. A: 5-HT 2B receptor agonist potency [pEC 50 ϭ Ϫlog(EC 50 )] for facilitating the LLR plotted against the agonist binding affinity to that receptor (pK i ), with each agonist name indicated next to its point. ␣-methyl-5-HT potency with and without block of 5-HT 2C receptor with RS102221 plotted. Thin line: linear correlation between potency and affinity. Dashed line: best fit line with unit slope (potency ϭ binding affinity ϩ C, where C ϳ -1). B-D: similar potencyaffinity scatter plots for the remaining 5-HT receptors. Agonists used for each receptor are listed in Table 1 , with agonists assumed to act at a receptor only if K i Ͻ400 nM. Potencies are from Table 2 . We used the potency of BW723C86 after treatment with SB204741 for the 5-HT 2C receptor plot to avoid dominant 5-HT 2B receptor action of this drug. Thin line: correlation between agonist potency and affinity for 5-HT 2C receptors. Dashed line: best fit unity slope relation for the 5-HT 2C receptor, copied into C and D to show lack of similar relation for other receptors. Other receptors had no significant correlation between potency and affinity (open circles; P Ͼ 0.05). ND and gray zone: no detected effect of agonist on the LLR.
5-HT 2B and 5-HT 2C receptors are not activated by endogenous 5-HT
Some of the 5-HT 2 receptor antagonists had no effect when given by themselves, including drugs selective to 5-HT 2B receptors (RS127445; Fig. 4B ) and 5-HT 2B/2C receptors (SB242084; Fig. 4D ) and the nonselective 5-HT 2 receptor antagonist methysergide (Table 4, column 7). All these drugs have previously been classified as neutral antagonists (Bonhaus et al. 1999; Chanrion et al. 2008; Westphal and Sanders-Bush 1994) . Neutral antagonists, by definition, only act to inhibit the action of 5-HT (endogenous or applied) or other agonists and have no effect when given by themselves (no intrinsic efficacy), because they do not block constitutive receptor activity (as we see in Table 4 ) (Chanrion et al. 2008; Seifert and Wenzel-Seifert 2002) . Thus the lack of effect of these drugs (when given alone) shows that there is no functional residual 5-HT activating 5-HT 2B or 5-HT 2C receptors in the spinal cord after chronic spinal injury, consistent with our recent report for 5-HT 2C receptors (Murray et al. 2010) .
5-HT 2B and 5-HT 2C receptors are constitutively active
The remaining 5-HT 2 receptor antagonists that we used, including those that bind selectively to 5-HT 2B receptors (SB204741), 5-HT 2C receptors (RS102221 and ketanserin), or both (SB206553), significantly inhibited the LLR when they were given by themselves (without prior agonist application; Table 4 ; Fig. 4, F and H) , thus suggesting that these compounds acted as inverse agonists, which by definition can block constitutive receptor activity (receptor activity in the absence of 5-HT), in addition to their conventional ability to antagonize 5-HT-induced receptor activity (Aloyo et al. 2009; Berg et al. 1999; Chanrion et al. 2008; Seifert and Wenzel-Seifert 2002; Weiner et al. 2001; Westphal and Sanders-Bush 1994) . Taken together with the lack of functional 5-HT in the chronic spinal rat, this inhibition of the LLR by such inverse agonists suggests that there is substantial constitutive activity in 5-HT 2B and 5-HT 2C receptors that endogenously facilitates the LLR. The magnitude of the inhibition of the LLR by SB204741 and RS102221 was similar (20 -30% reduction in LLR; Table 4 ), and thus the endogenous facilitation of the LLR is likely equally produced by constitutive activity in both 5-HT 2B and 5-HT 2C receptors. Furthermore, the inverse agonist SB206553, which selectively binds both 5-HT 2B and 5-HT 2C receptors (but no other receptors), reduced the PIC by approximately the amount predicted by the sum of the action of the selective 5-HT 2B and 5-HT 2C inverse agonist SB204741 and RS102221 (Table 4 ), suggesting that the action of 5-HT 2B and 5-HT 2C receptors is additive in facilitating the endogenous LLR (and associated LLR). The broad spectrum inverse agonists cyproheptadine and ketanserin also inhibited LLR (Table 4) . We have previously reported this action of SB206553 and cyproheptadine, but at the time we were only able to conclude that either 5-HT 2B or 5-HT 2C receptors may be constitutively active (Murray et al. 2010 ). Here we show that both receptors are constitutively active. The receptors for which the antagonists are selective are shown in column 2, along with K i values (parentheses). Receptors that the antagonists nonselectively bind at higher doses are shown in column 3, along with K i values. K i values were obtained from the following references, abbreviated in column 4 (Boess and Martin 1994; Bonhaus et al. 1999; Cussac et al. 2002; Knight et al. 2004; Vanover et al. 2004; Yoshio et al. 2001) . Selectivity is defined as the ratio of K i 's for two receptors (e.g., 470/1.1 ϭ 427-fold selectivity of RS127445 at 5-HT 2B over 5-HT 2C receptors). For the nonselective antagonists methysergide, cyproheptadine, and clozapine, only K i values for target receptors are shown, and other receptors affected only listed. Antagonists were used during LLR reflex testing at the doses indicated in column 5, with choice of dose based on K i values. Following application of the 5-HT 2 receptor agonist ␣-methyl-5-HT (0.3 M), antagonists were applied (Fig 4A) , and the inhibition of the agonist-induced LLR was measured (% change in LLR, relative to agonist-induced LLR; column 6; 0% no effect), with significant effects found for all 5-HT 2B or 5-HT 2C antagonists tested. Antagonists were also tested without agonists present to examine their negative efficacy (inverse agonist) action (e.g. Fig 4F) , and the inhibition of the control/basal LLR measured (% change in LLR; column 7), with significant effects found only for inverse agonists. The first 3 antagonists listed are neutral 5-HT 2B/2C receptor antagonists (no effect without agonist present, column 7), whereas the next 6 antagonists act as inverse agonists at 5-HT 2B/2C receptors (shaded rows; negative efficacy without agonist present, column 7). Data shown as mean Ϯ SD, with n Ͼ 8 per drug (or combination). -, not tested. *Significant inhibition induced by antagonist, P Ͻ 0.05.
Notably, cyproheptadine was the most effective of all inverse agonists tested, significantly exceeding the inhibition of the LLR produced by the 5-HT 2B/2C inverse agonist SB206553 (Table 4 ). This is likely because cyproheptadine potently inhibits both 5-HT 2 receptors and ␣1 adrenergic receptors (Westphal and Sanders-Bush 1994; Yoshio et al. 2001) (Table 4 ; ␣1 receptors, like 5-HT 2 receptors, are known to facilitate the LLR; Li et al. 2004b ). Also, the 5-HT 2C inverse agonist ketanserin produced significantly more inhibition of the LLR than the selective 5-HT 2C inverse agonist RS102221 (Table 4) . Again, this is likely because of the known potent binding of ketanserin to ␣1 receptors (Yoshio et al. 2001) , in addition to its 5-HT 2C receptors action (Cussac et al. 2002) (Table 4 ; ketanserin also binds potently to 5-HT 2A receptors, but these are not involved in modulating the LLR; see above). Together these data indicate that there is endogenous activity in ␣1 receptors, likely mediated by constitutive activity (consistent with Harvey et al. 2006b ), as with 5-HT 2 receptors; we address this issue in a separate paper (M. Rank and D. J. Bennett., unpublished data).
5-HT 2B and 5-HT 2C receptors regulate the Ca PIC in motoneurons
Considering that the LLR is mediated by the Ca PIC, it is likely that the 5-HT 2B and 5-HT 2C receptors modulate the Ca PIC, as they do to the LLR. To confirm this, we directly measured the Ca PIC in motoneurons using slow voltage ramps to inactivate transient currents and in the presence of TTX to synaptically isolate the motoneuron (by stopping spike-mediated transmission) and block the Na PIC, which can otherwise obscure the Ca PIC, as previously described (Harvey et al. 2006c) . During this slow voltage ramp (under voltage-clamp conditions), the Ca PIC was activated at, on average, Ϫ49.6 Ϯ 6.41 mV (V on , n ϭ 46 motoneurons), producing a downward deflection in the recorded current of 1.98 Ϯ 1.07 nA, which we took as an estimate of the Ca PIC amplitude (Fig. 5A, arrow ; previously verified to be mediated by L-type calcium channels; nimodipine-sensitive) (Li et al. 2004c ). Application of the 5-HT 2B/2C agonists ␣-methyl-5-HT (0.3 M), DOI (1 M), BW723C86 (1-2 M), and 5-HT (1 M) each significantly increased the Ca PIC amplitude (by Ϫ0.71 Ϯ 0.82 nA, n ϭ 11; Ϫ0.60 Ϯ 0.75, n ϭ 9; Ϫ0.42 Ϯ 0.43, n ϭ 15; and Ϫ0.58 Ϯ 0.68 nA, n ϭ 11; respectively; Figs. 4B and 5B), and lowered the onset threshold of the PIC, V on (by Ϫ7.9 Ϯ 8.0, Ϫ5.6 Ϯ 3.8, Ϫ3.8 Ϯ 2.2, and Ϫ6.3 Ϯ 4.7 mV, respectively). The 5-HT 2B/2C antagonist SB206553 (5 M) significantly inhibited the facilitation of the Ca PIC by ␣-methyl-5-HT (by -1.77 Ϯ 0.48 nA; Fig. 5, C and D) . Whereas the selective 5-HT 2B agonist BW723C86 increased the Ca PIC, its mean effect was one half that of the 5-HT 2B/2C agonist ␣-methyl-5-HT (see above), and subsequent application of the 5-HT 2B/2C agonist ␣-methyl-5-HT (0.3 M) after BW723C86 further significantly facilitated the Ca PIC (PIC increased by Ϫ0.43 Ϯ 0.55 nA; and V on lowered by Ϫ3.3 Ϯ 3 M; A) , whereas when applied alone RS127445 had no effect on the LLR (B). C and D: likewise, the neutral antagonist SB242084 (3 M; selective for 5-HT 2B and 5-HT 2C receptors) inhibited that same agonist induced LLR (C), whereas SB242084 had no effect when applied alone (D). E-H: in contrast, the inverse agonists RS102221 (3 M, selective for 5-HT 2C receptors) and SB206553 (5 M, selective for 5-HT 2B and 5-HT 2C receptors) inhibited the agonist-induced LLR (E and G) and inhibited the spontaneously occurring LLR when given alone (F and H) . Considering that inverse agonists block constitutive activity and agonistinduced activity, whereas neutral antagonists only block agonist induced activity, these results indicate that the 5-HT 2B and 5-HT 2C receptors exhibit constitutive activity and are not activated by endogenous residual 5-HT. See statistics in Table 4. 3.7 mV, n ϭ 9; Fig. 6 ), suggesting involvement of both 5-HT 2B and 5-HT 2C receptors. The agonists 8-OH-DPAT (3 M) and zolmitriptan (1 M) had no significant effects on motoneuron properties (Ca PIC unaffected; n ϭ 5, P Ͼ 0.05), confirming that 5-HT 1A/1B/1D/1F , 5-HT 5 , and 5-HT 7 receptors have no influence on the Ca PIC. Together these results verify that both 5-HT 2B and 5-HT 2C receptors are involved in facilitating Ca PIC in motoneurons, whereas other 5-HT receptors are not likely involved.
The 5-HT 2 receptor agonists ␣-methyl-5-HT, DOI, and BW723C86 did not significantly change the resting potential (changes: 2.4 Ϯ 9.2, Ϫ3.2 Ϯ 8.0, and Ϫ1.2 Ϯ 6.1 mV, respectively), consistent with previous reports that resting membrane potential is increased by 5-HT via a non-5-HT 2 receptor (Harvey et al. 2006a ). The input resistance was significantly increased by these 5-HT 2 receptor agonists (by 2.7 Ϯ 2.4, 0.79 Ϯ 0.89, and 0.85 Ϯ 1.15 M⍀, corresponding to 69, 21, and 18% increases, respectively). . 5-HT 2B and 5-HT 2C receptors facilitate the motoneuronal Ca PIC, as they do the LLR. A: Ca PIC in motoneuron of chronic spinal rat, activated by slowly increasing the membrane potential under voltage clamp, and quantified at its initial peak, where it produced a downward deflection in the recorded current (at arrow) relative to the leak current (thin line). V on represents the voltage at which the Ca PIC was activated. Horizontal dashed line indicates resting potential. Recording in presence of TTX (2 M) to block the Na PIC and synaptic input. B: the 5-HT 2 receptor agonist ␣-methyl-5-HT (0.1 M) increased the Ca PIC and reduced V on . C and D: in another motoneuron, the selective 5-HT 2B/2C antagonist SB206553 (5 M) reduced the agonist induced increase in the Ca PIC. Fig. 5 (in TTX, 2 M) . B: the moderately selective 5-HT 2B receptor agonist BW723C86 (1 M) increased the size of the Ca PIC and lowered its onset voltage.
5-HT 2B receptors are seen on motoneurons with immunolabeling
Considering that 5-HT 2B and 5-HT 2C receptor agonists increase the Ca PIC in the presence of TTX, it is likely that motoneurons of chronic spinal rats have both these receptors. Previously, we confirmed the presence of 5-HT 2C receptors on these motoneurons using immunolabeling (Murray et al. 2010) , and here we repeat this for 5-HT 2B receptors (Fig. 7) . Motoneurons were labeled with an antibody to a type of neurofilament H (SMI32; Fig. 7, red) that we have previously shown labels motoneurons and not interneurons in the ventral horn (Anelli et al. 2007) . Double labeling with a 5-HT 2B receptor antibody (green) showed a high degree of colocalization with SMI32 (yellow and orange), indicating the presence of this receptor on motoneurons, in all chronic spinal (n ϭ 6/6; Fig 7,  A-C) . As with the 5-HT 2C receptor (Murray et al. 2010 ), a large fraction of the 5-HT 2B receptor labeling was intracellular to the motoneurons (perinuclear), consistent with the tendency for constitutively active receptor isoforms to become internalized (Chanrion et al. 2008) . Similar 5-HT 2B labeling was seen on SMI32-labeled motoneurons in normal rats (n ϭ 7/7 rats; Fig. 7 , D-F). However, we did not try to quantify the difference between the labeling in normal and injured rats, because cords of injured rats generally perfuse less well with PFA, and this affects the antibody staining.
D I S C U S S I O N
Our results showed two novel concepts: first, the 5-HT 2B receptor modulates motoneuron excitability (Ca PICs) after SCI, and second, the 5-HT 2B receptor plays an essential role in the spontaneous recovery of motoneuron function after SCI, by exhibiting constitutive receptor activity. Constitutive 5-HT receptor activity has previously been shown in the CNS for 5-HT 2A and 5-HT 2C (De Deurwaerdere et al. 2004; Murray et al. 2010) receptors but not previously for 5-HT 2B receptors. The 5-HT 2B and 5-HT 2C receptors that we describe are on the motoneurons themselves, because receptor agonists increased the Ca PICs when synaptic transmission was blocked with TTX. In addition, immunolabeling confirms 5-HT 2B (Fig. 7) and 5-HT 2C (Murray et al. 2010 ) receptors on motoneurons in our preparation.
Considering that the Ca PIC is known to cause long-lasting motoneuron discharges evoked by brief stimuli (LLRs) (Li et al. 2004a,b) , we used these LLRs as an assay of the Ca PIC to efficiently estimate the dose-response relations for the Ca PIC/LLR for numerous drugs and to perform a thorough analysis of all 5-HT receptors, ruling out the involvement of all but the 5-HT 2B and 5-HT 2C receptors. We do not know why other receptors, including 5-HT 1A , 5-HT 2A , 5-HT 3 , and 5-HT 7 , do not facilitate the LLR, considering that these receptors are present in the spinal cord (Hochman et al. 2001; Millan 2002; Schmidt and Jordan 2000) and have previously been suggested to have multiple actions on motoneurons, reflexes, or locomotion (Dougherty et al. 2005; Hammar et al. 2007; Holohean et al. 1995; Shay et al. 2005; Ziskind-Conhaim et al. 1993 ) (see Introduction). The relatively selective 5-HT 3 receptor agonist 2-methyl-5-HT (3-fold selectivity in Table 1 ) (Alexander et al. 2004 ) and 5-HT 2A receptor agonist DOI (10-fold selectivity over other 5-HT 2 receptors; Table 1 ) did increase the LLR, but both these drugs worked at doses too high to be consistent with binding to these receptors and instead acted by their lower affinity binding to the 5-HT 2B receptor (Table 3 ; relative potency near -1) (Wainscott et al. 1993 ). This underscores the importance of considering the nonselective lower affinity binding of putative agonists, with quantitative comparisons to receptor binding affinity, which requires testing agonists at multiple doses and comparing across multiple agonists. Finally, in this study, we only examined the 5-HT receptors that facilitate the LLR and associated PIC; in a separate paper, we examine the receptors that inhibit sensory afferent transmission in the LLR pathway, which include the 5-HT 1B receptor (K. C. Murray, unpublished data) . showing extensive receptor distribution, including labeling of the soma of motoneurons (with nuclei labeled with n), as visualized with 0.14-m thin optical sections with confocal microscopy (n ϭ 6). B: double-labeling of the same tissue with SMI32 (red), a selective marker of motoneurons in the ventral horn, which specifically labels neurofilament in the intracellular space. C: an overlay of 5-HT 2B and SMI32-labeling shows extensive co-localization (yellow and orange), indicating 5-HT 2B receptors on motoneuron soma (arrow) and dendrites (d). D-F: typical immunolabeling of 5-HT 2B receptors SMI32 in the sacral ventral horn (below injury) of normal rats (n ϭ 7 rats). Note again the 5-HT 2B receptors on motoneurons, with yellow/orange co-localization with SMI32.
We did not expect a prominent role of the 5-HT 2B receptor, which is a relatively obscure receptor, first described in the stomach fundus and not widely expressed in the brain (Barnes and Sharp 1999; Hoyer et al. 2002; Nichols and Nichols 2008; Wainscott et al. 1993 ). In the brain (and heart), this receptor is mainly associated with developmental plasticity and pathology (knockouts of the 5-HT 2B receptor gene is lethal, unlike for other 5-HT receptors) (Barnes and Sharp 1999; Nichols and Nichols 2008) . Outside of reports of 5-HT 2B receptors modulating frog N-methyl-D-aspartate (NMDA) receptor function on spinal motoneurons (Hackman and Holohean 2010; Holohean and Hackman 2004) , little is known about the role of this receptor in the adult spinal cord, even though it is present in the spinal cord (Hochman et al. 2001; Holohean et al. 1992; Millan 2002) . Interestingly, 5-HT 2B receptor gene expression (mRNA) appears in rat sacral motoneurons, and this expression persists unchanged with long-term SCI . Considering its novelty, we used several approaches to prove the presence and functionality of the 5-HT 2B receptor, including showing that 1) 5-HT 2B agonists consistently facilitated motoneuron excitability (LLR and PICs), even when they were made highly selective by a prior block of other receptors known to be activated by the agonists (e.g., 5-HT 2C and 5-HT 2A receptors for DOI), 2) selective 5-HT 2B receptor antagonists overcame the agonist action, when given after a low dose of the agonist titrated to just activate 5-HT 2 receptors, 3) agonist action was highly correlated with 5-HT 2B binding affinity for the agonists at the 5-HT 2B receptor and indeed agonist potency could be quantitatively predicted from binding affinity, and 4) 5-HT 2B receptors are on the motoneurons (immunolabeling). The same methods were used to show that the 5-HT 2C receptor was also present and functional. In contrast, 5-HT 2A receptors were not functional in modulating the PICs, contrary to our previous erroneous conclusion that they modulated the PICs, based on data from the nonselective agonist DOI (Harvey et al. 2006a ). The 5-HT 2A receptors likely have other functions on motoneurons, because they are on motoneurons and are upregulated with injury (Kong et al. 2010) . Interestingly, both 5-HT 2B and 5-HT 2C receptors seem to have equally large effects, based on the action of selective agonists and antagonists.
An advantage of studying the action of 5-HT receptor agonists after chronic spinal transection or severe contusion is that 5-HT terminals and associated high-affinity serotonin reuptake transporters (SERTs) are mostly eliminated in the spinal cord by the injury (Hayashi et al. 2010; Murray et al. 2010; Newton and Hamill 1988) , so they cannot interfere with the action of exogenously applied 5-HT or other agonists [although there may remain some minor low-affinity plasma membrane monoamine transport (PMAT)] (Engel et al. 2004) . SERT is almost exclusively located on 5-HT neurons in the brain (explaining its loss with injury), and it regulates the amount of 5-HT in the synaptic cleft (Blakely et al. 1994) . Accordingly, SERT dramatically affects the dose of exogenously applied 5-HT needed to activate receptors in the synapse, and serotonin reuptake inhibitors that block SERT (citalopram) decrease the dose of 5-HT or other 5-HT agonists needed to facilitate motoneuron function by a factor of 30 (Elliott and Wallis 1992) (Bennett and Murray, unpublished data) . Thus the lack of synaptic SERT in the chronic spinal rat allows 5-HT to reach receptors unimpeded, and our estimates of drug potency (and EC 50 ) therefore are much more accurate.
Indeed, our previous work has shown that the in vitro dose of 5-HT needed to affect motoneurons in spinal cords from normal rats is dramatically higher (by a factor of 30; 10 vs. 0.3 M) than that in chronic spinal rats (Harvey et al. 2006a) . We suggest that this supersensitivity in chronic spinal rats is largely caused by the absence of SERT in chronic spinal rats, whereas in normal rats, SERT efficiently prevents much of the exogenously applied 5-HT from reaching the 5-HT receptors. This lack of SERT after injury may also explain the supersensitity seen to other 5-HT receptors agonists (Harvey et al. 2006a ), because SERT is rather promiscuous, transporting tryptamine-like compounds (Adkins et al. 2001; Henry et al. 2006) , including many common agonists that we use, such as ␣-methyl-5-HT, 2-Methyl-5-HT, 5-HT, 5-CT, and tryptamine (Adkins et al. 2001; Helfman et al. 1995; Henry et al. 2006 ) (␣-methyl-5-HT is abbreviated ␣-MST in Henry et al. 2006 ). In summary, our quantitative analysis of 5-HT receptor agonist potency and correlation to receptor binding affinity would not have been possible had we not been studying the fully transected rat that lacks SERT, because SERT interferes with agonists reaching the receptors in the normal spinal cord, effectively making the normal spinal cord much less sensitive to 5-HT agonists compared with the spinal cord of chronic spinal rats.
We found a remarkably consistent relation between agonist potency (-logEC 50 ) and receptor binding affinity (-logK i ). Basically, effective agonist doses (EC 50 ) were consistently only about 10 times the binding K i values of that agonist to 5-HT 2B receptors. Receptor binding affinities are typically measured in homogenized membranes from isolated cell culture systems where agonists are applied directly to the receptors (Boess and Martin 1994) , whereas in our whole spinal cord preparations, agonists must diffuse substantial distances to reach receptors (see RESULTS). Likely, this diffusion barrier in part helps explain the factor of 10 that relates EC 50 to K i values. Even disregarding the pia, diffusion in brain and spinal cord tissue is somewhat restricted, where diffusion coefficients for small molecules are 4 times lower than in saline (D* ϭ 5 ϫ 10 Ϫ7 cm 2 /s) (Nicholson and Tao 1993; Sykova and Nicholson 2008) , because of the convoluted and small extracellular space (only 20% of total volume) (Sykova and Nicholson 2008) . Considering that the motoneuron cell bodies in the S 4 -S 3 sacral spinal cord are about 0.25 mm below the surface and that we waited about 10 min for drugs to diffuse into the cord before recording, the diffusion equation indicates that the drug concentration at the motoneuron cell bodies should be only about 0.31 times the applied ACSF concentration (assuming D* ϭ 5 ϫ 10 Ϫ7 cm 2 /s, and 1D diffusion paths) (using Eq. 9 in Sykova and Nicholson 2008 ). If we also consider that the 5-HT receptors may be on motoneuron dendrites that can be even deeper in the tissue (say 0.4 mm), the concentration at these deep dendrites should be about 1/10th the applied surface concentration. In summary, diffusion can contribute substantially to our factor of 10 difference between EC 50 and K i . Interestingly, had we waited longer times between the drug application and recording, the drug concentrations in the cord would have been higher, and the EC 50 and K i would have been closer, although computing the EC 50 would have been difficult because of slow rundown of reflexes over the hours needed to construct such a dose-response relation.
Other factors like receptor reserve (pool of receptors) and downstream G protein signaling (Boess and Martin 1994) may also contribute to the higher EC 50 values (lower potency) in our system. Additionally, we compared our EC 50 values to K i values obtained from competitive binding between our agonists and radiolabeled agonists (e.g., [ 3 H]-5-HT; see METHODS). This generally labels a high affinity binding state that occurs in response to receptor activation. Had we instead compared with the low affinity binding obtained with radiolabeled antagonists, which do not activate the receptor (Egan et al. 2000; Knight et al. 2004) , the EC 50 and K i might have been closer.
Assuming that diffusion is the predominant factor in increasing our observed EC 50 and that diffusion affects all 5-HT receptor activation similarly (similar receptor depths), our observed factor-of-10 relation between EC 50 and K i may ultimately help us predict doses of agonist and antagonists needed to effectively activate any particular 5-HT receptor. Indeed, we used this to choose doses of antagonists (Table 4 ) and independently verified those doses by their action alone or against an agonist. We also used this simple relation to help rule out the involvement of receptors other than 5-HT 2B and 5-HT 2C ; these other receptors had EC 50 /K i ratios far from 10. With this method and direct use of agonists to other receptors (8-OH-DPAT, etc.), it is clear that no other 5-HT receptor is involved in modulating the Ca PIC and associated LLR. Different agonists have variable functional efficacy (partial or full agonists) (Kenakin 1996) , but we avoided this issue by focusing on binding affinity and potency rather than efficacy. However, a caveat that must be noted is that we do not know for certain that all drugs that bind to a receptor act as an agonist at that receptor, and indeed, compounds like 8-OH-DPAT have poor efficacy (partial agonists) at some receptors to which they bind (e.g., 5-HT 7 for 8-OH-DPAT) (Eglen et al. 1997 ); thus we also tested more effective agonists to these receptors (LP44).
Both 5-HT 2B and 5-HT 2C receptors are Gq protein-coupled receptors that generally activate the classic PLC (phospholipase C) pathways involved in the synthesis of inositol phosphates (IP) and mobilization of intracellular Ca 2ϩ stores (Hoyer et al. 2002; Kenakin 1996; Lucaites et al. 1996; Mizuno and Itoh 2009 ). These pathways facilitate PICs (and NMDA receptors) in spinal motoneurons (Holohean and Hackman 2004; Mejia-Gervacio et al. 2004; Perrier et al. 2000) . Thus it is likely that the 5-HT 2B and 5-HT 2C receptors modulate the PICs via IP pathways in our preparation. Both these receptor types are known to exhibit a substantial degree of constitutive activity (Seifert and Wenzel-Seifert 2002; Villazon et al. 2003; Weiner et al. 2001) , usually observed in the form of IP production in the absence of 5-HT (or other agonists), which produces a basal level of IP (Chanrion et al. 2008; Kennett et al. 1997b; Knight et al. 2004 ). Thus, PICs may in part be facilitated by this basal IP production (without 5-HT), and this may explain the emergence of the large PICs seen after SCI when there is an absence of 5-HT, as we discuss below. Importantly, the subclass of antagonists known as inverse agonists inhibit this basal IP production (or associated functions) in 5-HT 2B and 5-HT 2C receptors, including classic antagonists such as cyproheptadine, clozapine, and ketanserin (Chanrion et al. 2008; Villazon et al. 2003; Weiner et al. 2001; Westphal and Sanders-Bush 1994) . In contrast, neutral antagonists like methysergide and RS127445 have no effect when given alone (Bonhaus et al. 1999; Chanrion et al. 2008; Westphal and Sanders-Bush 1994) . Therefore, a combination of these drugs is useful in identifying constitutive activity. Both inverse agonists and neutral antagonists block the action of agonists, and thus the action of an inverse agonist alone is not sufficient to prove the presence of constitutive receptor activity, if there is any chance that the receptor is activated by 5-HT (e.g., residual 5-HT in the spinal cord). Definitive proof of constitutive activity only comes by also showing that neutral antagonists have no effect (as in Table 4 ) (Seifert and Wenzel-Seifert 2002) .
Brain stem-derived 5-HT normally serves a critical role in tuning the excitability of motoneurons, facilitating Ca PICs that amplify and prolong responses to synaptic input (Heckman et al. 2005) . Thus, when SCI eliminates this major source of 5-HT, motoneurons are initially left in a depressed state and are not able to produce adequate muscle contractions. However, over the weeks after injury, Ca PICs in motoneurons spontaneously recover, to the point where they are permanently large, and not only help with residual motor functions but also contribute to unwanted contractions (muscle spasms) Li et al. 2004a) . Recently, we showed that a novel form of plasticity in 5-HT 2 receptors causes this recovery of Ca PICs: these receptors become spontaneously active in the absence of 5-HT (constitutively active) (Murray et al. 2010) . However, at the time, we were uncertain which particular 5-HT 2 receptor modulates the Ca PIC. The present results resolve this issue, showing that both 5-HT 2B and 5-HT 2C receptors are constitutively active after SCI, because selective 5-HT 2B and 5-HT 2C inverse agonists that block this constitutive activity decrease motoneuron excitability (LLRs and associated Ca PICs), whereas neutral antagonists do not. As discussed above, the lack of effect of neutral antagonists shows that there is no residual 5-HT below the chronic injury that activates the 5-HT 2 receptors. Thus, even though the inverse agonists we tested can block the action of 5-HT, in addition to blocking constitutive receptor activity, their action can only be attributed to constitutive 5-HT 2B and 5-HT 2C receptor activity. Considering that most known antagonists can act as inverse agonists at 5-HT 2B and 5-HT 2C receptors in various model systems, whereas neutral antagonists are rare (Weiner et al. 2001; Westphal and Sanders-Bush 1994) , we were not surprised that the selective 5-HT 2B and 5-HT 2C receptor antagonists (SB204741 and RS102221, respectively) could act as inverse agonists in inhibiting the LLR. However, we had not anticipated such prominent constitutive activity in 5-HT 2B receptors, as shown by these compounds, because constitutive activity in this receptor has not previously been shown in the CNS, although it has been seen in the stomach fundus (Villazon et al. 2003) .
The constitutive 5-HT 2 receptor activity that we observed after SCI arises from at least two mechanisms. First, there is an increase in expression of 5-HT 2C receptor isoforms that exhibit a high degree of constitutive activity (Murray et al. 2010 ).
Most 5-HT 2C receptor isoforms have some probability of being constitutively active, but certain isoforms, like the INI isoform, have a very high degree of constitutive activity (with activity approaching that produced by maximal activation with 5-HT) (Berg et al. 2008; Herrick-Davis et al. 1999; Marion et al. 2004; Weiner et al. 2001) , and these isoforms increase in expression with SCI (Murray et al. 2010) . Second, the total number of 5-HT 2C receptors increases with SCI (Hayashi et al. 2010) , which increases overall constitutive activity because all isoforms exhibit some constitutive activity (Berg et al. 2008; Herrick-Davis et al. 1999 ). We do not know whether the 5-HT 2B receptor isoform types or total receptor numbers change with injury, although we do know that the 5-HT 2B receptor gene expression is unchanged with long-term SCI .
In summary, we performed a systematic analysis of the 5-HT receptors that facilitate motoneuron PICs and associated LLRs (spasms) after SCI and found that both 5-HT 2B and 5-HT 2C receptors are involved, whereas 5-HT 1 , 5-HT 2A , and 5-HT 3/4/5/6/7 receptors are not. Although both 5-HT 2B and 5-HT 2C receptors are present before injury, they exhibit dramatic plasticity after chronic spinal transection, presumably as a compensation for the nearcomplete loss of 5-HT innervation. That is, both receptors become constitutively active, producing large Ca PICs in the absence of 5-HT (whereas acutely after injury, PICs are small). These large Ca PICs are essential for the recovery of normal motoneuron firing ability after chronic injury (sustained firing and amplification of synaptic input) (Harvey et al. 2006c; Heckman et al. 2005) and thus must play an important role in all motor recovery, including locomotion (Murray et al. 2010) . However, unlike with normal brain stem control over receptor activation, these receptors are permanently active, leading to permanently large PICs and ultimately hyperexcitability of motoneurons associated with muscle spasms. Thus controlling excess constitutive activity in 5-HT 2 receptors, especially 5-HT 2B receptors, offers a new approach in managing spasticity after SCI. 
